Summary by Moomoo AI
On December 31, 2023, Armistice Capital, LLC and Steven Boyd filed a Schedule 13G with the SEC, disclosing a 9.99% ownership stake in Vivos Therapeutics, Inc., amounting to 175,099 shares. Armistice Capital, as the investment manager of Armistice Capital Master Fund Ltd., exercises voting and investment power over the securities held by the Master Fund. Steven Boyd, as the managing member of Armistice Capital, may also be deemed to beneficially own the securities held by the Master Fund. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Vivos Therapeutics. The filing was signed and dated February 14, 2024, by Steven Boyd, Managing Member of Armistice Capital, LLC.